Mnk2 alternative splicing modulates the p38-MAPK pathway and impacts Ras-induced transformation
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Maimon, AvrahamMogilevsky, Maxim
Shilo, Asaf
Golan-Gerstl, Regina
Obiedat, Akram
Ben-Hur, Vered
Lebenthal-Loinger, Ilana
Stein, Ilan
Reich, Reuven
Beenstock, Jonah
Zehorai, Eldar
Andersen, Claus L.
Thorsen, Kasper
Orntoft, Torben F.
Davis, Roger J.
Davidson, Ben
Mu, David
Karni, Rotem
UMass Chan Affiliations
Program in Molecular MedicineDocument Type
Journal ArticlePublication Date
2014-04-24Keywords
Active Transport, Cell Nucleus*Alternative Splicing
Animals
Cell Nucleus
Cell Transformation, Neoplastic
*MAP Kinase Signaling System
Mice
Protein Binding
Protein-Serine-Threonine Kinases
p38 Mitogen-Activated Protein Kinases
ras Proteins
Biochemistry
Cell Biology
Cells
Cellular and Molecular Physiology
Enzymes and Coenzymes
Genetic Phenomena
Investigative Techniques
Molecular Biology
Neoplasms
Skin and Connective Tissue Diseases
Metadata
Show full item recordAbstract
The kinase Mnk2 is a substrate of the MAPK pathway and phosphorylates the translation initiation factor eIF4E. In humans, MKNK2, the gene encoding for Mnk2, is alternatively spliced yielding two splicing isoforms with differing last exons: Mnk2a, which contains a MAPK-binding domain, and Mnk2b, which lacks it. We found that the Mnk2a isoform is downregulated in breast, lung, and colon tumors and is tumor suppressive. Mnk2a directly interacts with, phosphorylates, activates, and translocates p38alpha-MAPK into the nucleus, leading to activation of its target genes, increasing cell death and suppression of Ras-induced transformation. Alternatively, Mnk2b is pro-oncogenic and does not activate p38-MAPK, while still enhancing eIF4E phosphorylation. We further show that Mnk2a colocalization with p38alpha-MAPK in the nucleus is both required and sufficient for its tumor-suppressive activity. Thus, Mnk2a downregulation by alternative splicing is a tumor suppressor mechanism that is lost in some breast, lung, and colon tumors.Source
Cell Rep. 2014 Apr 24;7(2):501-13. doi: 10.1016/j.celrep.2014.03.041. Epub 2014 Apr 13. Link to article on publisher's site
DOI
10.1016/j.celrep.2014.03.041Permanent Link to this Item
http://hdl.handle.net/20.500.14038/28321PubMed ID
24726367Related Resources
Rights
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Distribution License
http://creativecommons.org/licenses/by-nc-nd/3.0/ae974a485f413a2113503eed53cd6c53
10.1016/j.celrep.2014.03.041
Scopus Count
Collections
Except where otherwise noted, this item's license is described as <p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).</p>

